These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 2619987)

  • 1. [Formal requirements and a cultural approach to the control of slow-release dosage forms].
    Ciranni Signoretti E
    Boll Chim Farm; 1989 Jun; 128(6):199-201. PubMed ID: 2619987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmaceutical design and development of a Sinemet controlled-release formulation.
    Dempski RE; Scholtz EC; Oberholtzer ER; Yeh KC
    Neurology; 1989 Nov; 39(11 Suppl 2):20-4. PubMed ID: 2685648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Study on index for formulation optimization of sustained or controlled released dosage forms].
    Hong YL; Feng Y; Xu DS
    Zhongguo Zhong Yao Za Zhi; 2006 Jan; 31(1):15-7. PubMed ID: 16548158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mini review of scientific and pharmacopeial requirements for the disintegration test.
    Donauer N; Löbenberg R
    Int J Pharm; 2007 Dec; 345(1-2):2-8. PubMed ID: 17935916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellulose hydrogen phthalate. A coating polymer in controlled release dosage forms.
    Dor P; Benita S; Levesque G
    Pharm Acta Helv; 1987; 62(9):255-61. PubMed ID: 3423094
    [No Abstract]   [Full Text] [Related]  

  • 6. Regulatory aspects of modified release dosage forms: special cases of dissolution testing using the flow-through system.
    Möller H; Wirbitzki E
    Boll Chim Farm; 1993 Apr; 132(4):105-15. PubMed ID: 8333916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Research and development of oral controlled-release dosage forms].
    Moës AJ
    J Pharm Belg; 1989; 44(1):60-70. PubMed ID: 2656982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained release veterinary parenteral products.
    Medlicott NJ; Waldron NA; Foster TP
    Adv Drug Deliv Rev; 2004 Jun; 56(10):1345-65. PubMed ID: 15191786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral controlled release optimization of pellets prepared by extrusion-spheronization processing.
    Bianchini R; Vecchio C
    Farmaco; 1989 Jun; 44(6):645-54. PubMed ID: 2803450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Workshop II report: scaleup of oral extended release dosage forms.
    Skelly JP; Van Buskirk GA; Arbit HM; Amidon GL; Augsburger L; Barr WH; Berge S; Clevenger J; Dighe S; Fawzi M
    J Pharm Sci Technol; 1994; 48(2):95-101. PubMed ID: 8032802
    [No Abstract]   [Full Text] [Related]  

  • 11. Conception of peroral sustained-release dosage forms: calculation of initial and maintenance dose with consideration of accumulation.
    Förster H; Lippold BC
    Pharm Acta Helv; 1982; 57(12):345-9. PubMed ID: 7156173
    [No Abstract]   [Full Text] [Related]  

  • 12. [The effect of different variables on the in vitro dissolution of a theophylline sustained-release preparation].
    Fuchs WS; Jakobs R; Grunenberg P; Weiss G; Profitlich T; von Nieciecki A; Klemm FH; Laicher A; Stanislaus F
    Arzneimittelforschung; 1998 May; 48(5A):552-6. PubMed ID: 9676343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the characteristics of oral dosage forms with release controlled by erosion.
    Rosca ID; Vergnaud JM
    Comput Biol Med; 2008 Jun; 38(6):668-75. PubMed ID: 18455158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Per-oral controlled release dosage form of theophylline using soybean protein.
    Machida Y; Tokumura T; Nagai T
    Drug Des Deliv; 1987 Feb; 1(3):187-92. PubMed ID: 3509332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diclofenac sodium multisource prolonged release tablets--a comparative study on the dissolution profiles.
    Bertocchi P; Antoniella E; Valvo L; Alimonti S; Memoli A
    J Pharm Biomed Anal; 2005 Apr; 37(4):679-85. PubMed ID: 15797788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of dissolution profiles obtained from nifedipine extended release once a day products using different dissolution test apparatuses.
    Garbacz G; Golke B; Wedemeyer RS; Axell M; Söderlind E; Abrahamsson B; Weitschies W
    Eur J Pharm Sci; 2009 Sep; 38(2):147-55. PubMed ID: 19591927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Theophylline controlled-release formulations: in vivo-in vitro correlations.
    Yu Z; Schwartz JB; Sugita ET
    Biopharm Drug Dispos; 1996 Apr; 17(3):259-72. PubMed ID: 8983400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of poloxamer on the dissolution of felodipine and preparation of controlled release matrix tablets containing felodipine.
    Lee KR; Kim EJ; Seo SW; Choi HK
    Arch Pharm Res; 2008 Aug; 31(8):1023-8. PubMed ID: 18787792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probability of passing dissolution acceptance criteria for an immediate release tablet.
    Dumont ML; Berry MR; Nickerson B
    J Pharm Biomed Anal; 2007 May; 44(1):79-84. PubMed ID: 17379465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative evaluation of plastic, hydrophobic and hydrophilic polymers as matrices for controlled-release drug delivery.
    Reza MS; Quadir MA; Haider SS
    J Pharm Pharm Sci; 2003; 6(2):282-91. PubMed ID: 12935440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.